Does pioglitazone reduce carotid intima–media thickness in patients with type 2 diabetes mellitus?
Cyrus Desouza
Correspondence Section of Diabetes, Endocrinology and Metabolism, 983020 University of Nebraska Medical Center, Omaha, NE 68198-3020, USA
Email cdesouza@unmc.edu
This article has no abstract so we have provided the first paragraph of the full text.
Patients with T2DM have greater cardiovascular risk than patients without T2DM, an observation that cannot be fully explained by the presence of traditional risk factors, such as hypertension, hyperglycemia and dyslipidemia. Other risk factors that cluster with insulin resistance, such as oxidative stress, inflammation and endothelial dysfunction, could be responsible for some of this risk.1 Small studies have shown that treatment with thiazolidinediones might improve these nontraditional, cardiovascular risk factors, possibly by direct effects on inflammation and cellular cholesterol efflux, independent of insulin sensitization.2 Mazzone et al. report the results of the large, multicenter CHICAGO study, which examined the effect of thiazolidinediones on CIMT.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
